Esperion Therapeutics Inc  

(Public, NASDAQ:ESPR)   Watch this stock  
Find more results for ESPR
+0.70 (1.25%)
After Hours: 56.70 +0.19 (0.34%)
Nov 24, 1:10PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 54.86 - 57.61
52 week 10.30 - 57.67
Open 55.84
Vol / Avg. 203,108.00/510,964.00
Mkt cap 1.45B
P/E     -
Div/yield     -
EPS -6.86
Shares 26.20M
Beta 2.62
Inst. own 107%
Feb 20, 2018
Q4 2017 Esperion Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 16, 2017
Esperion Therapeutics Inc at Jefferies Global Healthcare Conference
Nov 14, 2017
Esperion Therapeutics Inc at Stifel Healthcare Conference
Nov 7, 2017
Q3 2017 Esperion Therapeutics Inc Earnings Release
Oct 17, 2017
Esperion Therapeutics Inc Analyst and Investor Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.79% -27.73%
Return on average equity -83.93% -29.07%
Employees 44 -
CDP Score - -


3891 Ranchero Dr Ste 150
ANN ARBOR, MI 48108-2837
United States - Map
+1-734-8873903 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Officers and directors

Timothy M. Mayleben President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Narendra D. Lalwani Ph.D., FAHA, DABT Chief Operating Officer, Executive Vice President - Research & Development
Age: 64
Bio & Compensation  - Reuters
Mary P. McGowan M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Nicole Vitullo MBA Independent Lead Director
Age: 59
Bio & Compensation  - Reuters
Roger S. Newton Ph.D., FAHA, FACN Director
Age: 66
Bio & Compensation  - Reuters
Scott N. Braunstein M.D. Independent Director
Age: 53
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Antonio M. Gotto Jr., M.D., Ph.D. Independent Director
Age: 82
Bio & Compensation  - Reuters